What I do:
I advise emerging growth companies and investors on a wide range of China-related corporate matters including formation, governance, venture capital financings, mergers and acquisitions and public offerings. I also work on cross-border commercial transactions, including licensing, joint venture, manufacturing and distribution arrangements in the life sciences, digital media, cleantech and technology sectors.
Why Cooley in China:
After shuttling between Cooley Shanghai and San Diego for a couple of years, I decided that China is the place to be. It’s really exciting to be part of the fast-paced, action-driven emerging company ecosystem in China and assist aspiring entrepreneurs and seasoned investors with building transformative businesses.
What my clients value:
Being strategic, innovative, responsive, resourceful, pragmatic and result orientated. Understanding clients’ businesses and providing legal advice and solutions that make good business sense.
Some of my clients:
Aliph/Jawbone, BioPharm Solutions, Cenova Ventures, Cerus, Ceyuan Ventures, Chengwei Capital, Crown Bioscience, Equity Solar, Flatirons Solutions, GGV Capital, Glasspoint, ShaghaiTech University, iZENEtech, MakerBot, MobileIron, NeoPhotonics, NuVasive, Polaris Pharmaceuticals, Rally Software, Redpoint Ventures, RuiYi, Seattle Genetics, Tapatalk, US Renewables Group, Waterstone Pharmaceuticals and Yuan Capital
I root for:
Chicago Bulls and Barcelona
Business Adventures by John Brooks